BioAtla, Inc. (BCAB)

Market Cap	151.53M
Revenue (ttm)	n/a
Net Income (ttm)	-119.24M
Shares Out	48.11M
EPS (ttm)	-2.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	578,615
Open	3.000
Previous Close	3.000
Day's Range	2.920 - 3.320
52-Week Range	1.240 - 4.020
Beta	1.21
Analysts	Strong Buy
Price Target	14.50 (+367.74%)
Earnings Date	May 14, 2024

About BCAB

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of mela...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2020
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: BCAB

Analyst Forecast

According to 4 analysts, the average rating for BCAB stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 367.74% from the latest price.

Price Target

$14.5

(367.74% upside)

Analyst Consensus: Strong Buy